Pembrolizumab-induced nephrotoxicity in a patient with breast cancer

By sjmartinez • April 29, 2024

Alkassis S, Fitzsimmons K, Hurvitz S. Pembrolizumab-induced nephrotoxicity in a patient with breast cancer. Ther Adv Med Oncol. 2024 Apr 25;16:17588359241248362. doi: 10.1177/17588359241248362. PMID: 38680292; PMCID: PMC11047248.

Tags: adverse event management, breast cancer, Checkpoint Inhibitor, Fellow, Hematology/Oncology, immune-related adverse events, immune-related adverse events < immunotherapy, immunotherapy, Publications

Related Posts

Results from a phase 1b study of telisotuzumab vedotin in combination with osimertinib in patients with c-Met protein-overexpressing, EGFR-mutated locally advanced/metastatic non-small cell lung cancer (NSCLC) after progression on prior osimertinib

Horinouchi H, Cho BC, Camidge DR, Goto K, Tomasini P, Li Y, Vasilopoulos A, Brunsdon P, Hoffman D, Shi W, Bolotin E, Blot V, Goldman[...]

ZNFX1 functions as a master regulator of epigenetically induced pathogen mimicry and inflammasome signaling in cancer

Stojanovic L, Abbotts R, Tripathi K, Coon CM, Rajendran S, Abbasi Farid E, Hostetter G, Guarnieri JW, Wallace DC, Liu S, Wan J, Calendo G,[...]

Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study

Kudo M, Ren Z, Guo Y, Han G, Lin H, Zheng J, Ogasawara S, Kim JH, Zhao H, Li C, Madoff DC, Ghobrial RM, Kawaoka[...]